Literature DB >> 6406129

The ventilatory effects of doxapram in normal man.

P M Calverley, R H Robson, P K Wraith, L F Prescott, D C Flenley.   

Abstract

1. To determine the mode of action of doxapram in man we have measured ventilation, oxygen uptake, CO2 production, hypoxic and hypercapnic ventilatory responses in six healthy men before and during intravenous infusion to maintain a constant plasma level. 2. Doxapram changed neither resting oxygen uptake nor CO2 production but produced a substantial increase in resting ventilation at both levels of end-tidal CO2 studied. 3. Doxapram increased the ventilatory response to isocapnic hypoxia from -0.8 +/- 0.4 litre min-1 (%SaO2)-1 to -1.63 +/- 0.9 litres min-1 (%SaO2)-1. This was similar to the increase in hypoxic sensitivity which resulted from raising the end-tidal CO2 by 0.5 kPa without adding doxapram. 4. The slope of the ventilatory response to rebreathing CO2 rose from 11.6 +/- 5.3 litres min-1 kPa-1 to 20.4 +/- 9.8 litres min-1 kPa-1 during doxapram infusion. 5. The marked increase in the ventilatory response to CO2 implies that doxapram has a central action, but the potentiation of the hypoxic drive also suggests that the drug acts on peripheral chemoreceptors, or upon their central connections, at therapeutic concentrations in normal unanaesthetized subjects.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6406129     DOI: 10.1042/cs0650065

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  11 in total

1.  Serum doxapram and respiratory neuromuscular drive in normal man.

Authors:  S Okubo; K Konno; T Ishizaki; T Suganuma; T Takubo; T Takizawa; M Tanaka
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 2.  A new look at the respiratory stimulant doxapram.

Authors:  C Spencer Yost
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

Review 3.  Clinical features, pathogenesis and management of drug-induced seizures.

Authors:  G Zaccara; G C Muscas; A Messori
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

4.  A simple method for the administration of doxapram.

Authors:  M Mattila; I Larma
Journal:  Br J Clin Pharmacol       Date:  1987-03       Impact factor: 4.335

5.  Heart rate and respiratory response to doxapram in patients with panic disorder.

Authors:  Jose M Martinez; Amir Garakani; Cindy J Aaronson; Jack M Gorman
Journal:  Psychiatry Res       Date:  2015-03-09       Impact factor: 3.222

6.  Comparison of the acute effects on gas exchange of nasal ventilation and doxapram in exacerbations of chronic obstructive pulmonary disease.

Authors:  R M Angus; A A Ahmed; L J Fenwick; A J Peacock
Journal:  Thorax       Date:  1996-10       Impact factor: 9.139

Review 7.  Treatment of apnea of prematurity.

Authors:  Varsha Bhatt-Mehta; Robert E Schumacher
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

8.  The effect of doxapram on brain imaging in patients with panic disorder.

Authors:  Amir Garakani; Monte S Buchsbaum; Randall E Newmark; Chelain Goodman; Cindy J Aaronson; Jose M Martinez; Yuliya Torosjan; King-Wai Chu; Jack M Gorman
Journal:  Eur Neuropsychopharmacol       Date:  2007-06-08       Impact factor: 4.600

9.  Doxapram only slightly reduces the shivering threshold in healthy volunteers.

Authors:  Ryu Komatsu; Papiya Sengupta; Grigory Cherynak; Anupama Wadhwa; Daniel I Sessler; Jin Liu; Harrell E Hurst; Rainer Lenhardt
Journal:  Anesth Analg       Date:  2005-11       Impact factor: 6.627

Review 10.  Oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Simon E Brill; Jadwiga A Wedzicha
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-11-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.